Skip to main content
Top
Published in: Infectious Diseases and Therapy 1/2021

Open Access 01-03-2021 | Amphotericin B | Original Research

Cryptococcemia According to Immune Status: An Analysis of 65 Critical Cases

Authors: Ruochan Chen, Yiya Zhang, Pengcheng Zhou, Xiao Zhong, Mingxiang Zou, Yanming Li, Yan Huang

Published in: Infectious Diseases and Therapy | Issue 1/2021

Login to get access

Abstract

Introduction

Cryptococcemia is associated with poor prognosis among patients with cryptococcosis. However, there are limited data on the clinical features of cryptococcemia, particularly among patients with different immune statuses. This study assessed the largest number of cases diagnosed with cryptococcemia, to the best of our knowledge.

Methods

Demographic and clinical data of patients with positive blood culture results for Cryptococcus were obtained from medical records at the Xiangya Hospital (2010–2019).

Results

A total of 65 patients were diagnosed and treated for cryptococcemia, of which 53 (82%) immunosuppressed patients were afflicted with HIV (12%, 8/65), tuberculosis (8%, 5/26), liver cirrhosis (6%, 3/65), chronic renal failure (6%, 3/65), nephrotic syndrome (13%, 7/65), systemic lupus erythematosus (8%, 5/65), chronic glomerulonephritis (11%, 6/65), malignant diseases (19%, 10/65), and diabetes (11%, 6/65). Most patients (85%, 55/65) presented with fever. Other symptoms, such as cough, headache, enlarged lymph nodes, liver, or spleen, and septic shock, were also reported. Typically, the sites of infection included the central nervous system, lung, skin, bone, abdomen, endometrium, lymph node, and blood. Although early systemic antifungal therapy was administered to 61 patients within 48 h of hospitalization, the 60-day mortality rate was higher in the immunosuppressed group (53%) than in the immunocompetent group (8%).

Conclusions

Our study indicated that patients with different immune statuses presented different clinical features. Immunosuppressed patients with cryptococcemia presented a higher risk of mortality with poor prognosis, which required intense attention and treatment in time.
Literature
1.
go back to reference Chen SC, Korman TM, Slavin MA, et al. Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clin Infect. 2013;57:543–51.CrossRef Chen SC, Korman TM, Slavin MA, et al. Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clin Infect. 2013;57:543–51.CrossRef
2.
go back to reference Yuchong C, Fubin C, Jianghan C, et al. Cryptococcosis in China (1985–2010): review of cases from Chinese database. Mycopathologia. 2012;173:329–35.CrossRef Yuchong C, Fubin C, Jianghan C, et al. Cryptococcosis in China (1985–2010): review of cases from Chinese database. Mycopathologia. 2012;173:329–35.CrossRef
3.
go back to reference Archibald LK, McDonald LC, Rheanpumikankit S, et al. Fever and human immunodeficiency virus infection as sentinels for emerging mycobacterial and fungal bloodstream infections in hospitalized patients >/=15 years old. Bangk J Infect Dis. 1999;180:87–92.CrossRef Archibald LK, McDonald LC, Rheanpumikankit S, et al. Fever and human immunodeficiency virus infection as sentinels for emerging mycobacterial and fungal bloodstream infections in hospitalized patients >/=15 years old. Bangk J Infect Dis. 1999;180:87–92.CrossRef
4.
go back to reference Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med. 1974;80:176–81.CrossRef Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med. 1974;80:176–81.CrossRef
5.
go back to reference Pasqualotto AC, Bittencourt Severo C, de Mattos OF, Severo LC. Cryptococcemia. An analysis of 28 cases with emphasis on the clinical outcome and its etiologic agent. Rev Iberoam Micol. 2004;21:143–6.PubMed Pasqualotto AC, Bittencourt Severo C, de Mattos OF, Severo LC. Cryptococcemia. An analysis of 28 cases with emphasis on the clinical outcome and its etiologic agent. Rev Iberoam Micol. 2004;21:143–6.PubMed
6.
go back to reference Jean SS, Fang CT, Shau WY, et al. Cryptococcaemia: clinical features and prognostic factors. QJM. 2002;95:511–8.CrossRef Jean SS, Fang CT, Shau WY, et al. Cryptococcaemia: clinical features and prognostic factors. QJM. 2002;95:511–8.CrossRef
7.
go back to reference Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801–10.CrossRef Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801–10.CrossRef
8.
go back to reference Maertens JA, Girmenia C, Brüggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult hematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221–30.PubMed Maertens JA, Girmenia C, Brüggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult hematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221–30.PubMed
9.
go back to reference Illnait-Zaragozi MT, Martinez-Machin GF, Fernandez-Andreu CM, Perurena-Lancha MR, Hagen F, Meis JF. Cryptococcus and cryptococcosis in Cuba. A minireview. Mycoses. 2014;57:707–17.CrossRef Illnait-Zaragozi MT, Martinez-Machin GF, Fernandez-Andreu CM, Perurena-Lancha MR, Hagen F, Meis JF. Cryptococcus and cryptococcosis in Cuba. A minireview. Mycoses. 2014;57:707–17.CrossRef
10.
go back to reference Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med. 1989;321:794–9.CrossRef Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med. 1989;321:794–9.CrossRef
11.
go back to reference Hawkins C, Armstrong D. Fungal infections in the immunocompromised host. Clin Haematol. 1984;13:599–630.PubMed Hawkins C, Armstrong D. Fungal infections in the immunocompromised host. Clin Haematol. 1984;13:599–630.PubMed
12.
go back to reference Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann Intern Med. 1986;104:234–40.CrossRef Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann Intern Med. 1986;104:234–40.CrossRef
13.
go back to reference Mabee CL, Mabee SW, Kirkpatrick RB, Koletar SL. Cirrhosis: a risk factor for cryptococcal peritonitis. Am J Gastroenterol. 1995;90:2042–5.PubMed Mabee CL, Mabee SW, Kirkpatrick RB, Koletar SL. Cirrhosis: a risk factor for cryptococcal peritonitis. Am J Gastroenterol. 1995;90:2042–5.PubMed
14.
go back to reference Marwaha RK, Trehan A, Jayashree K, Vasishta RK. Hypereosinophilia in disseminated cryptococcal disease. Pediatr Infect Dis J. 1995;14:1102–3.CrossRef Marwaha RK, Trehan A, Jayashree K, Vasishta RK. Hypereosinophilia in disseminated cryptococcal disease. Pediatr Infect Dis J. 1995;14:1102–3.CrossRef
15.
go back to reference Sia JK, Georgieva M, Rengarajan J. Innate immune defenses in human tuberculosis: an overview of the interactions between mycobacterium tuberculosis and innate immune cells. J Immunol Res. 2015;2015:747543.CrossRef Sia JK, Georgieva M, Rengarajan J. Innate immune defenses in human tuberculosis: an overview of the interactions between mycobacterium tuberculosis and innate immune cells. J Immunol Res. 2015;2015:747543.CrossRef
16.
go back to reference Killick KE, Ní Cheallaigh C, O’Farrelly C, et al. Receptor-mediated recognition of mycobacterial pathogens. Cell Microbiol. 2013;15(9):1484–95.CrossRef Killick KE, Ní Cheallaigh C, O’Farrelly C, et al. Receptor-mediated recognition of mycobacterial pathogens. Cell Microbiol. 2013;15(9):1484–95.CrossRef
17.
go back to reference Liu CH, Liu H, Ge B. Innate immunity in tuberculosis: host defense vs pathogen evasion. Cell Mol Immunol. 2017;14(12):963–75.CrossRef Liu CH, Liu H, Ge B. Innate immunity in tuberculosis: host defense vs pathogen evasion. Cell Mol Immunol. 2017;14(12):963–75.CrossRef
18.
go back to reference Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect. 2010;50:291–322.CrossRef Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect. 2010;50:291–322.CrossRef
Metadata
Title
Cryptococcemia According to Immune Status: An Analysis of 65 Critical Cases
Authors
Ruochan Chen
Yiya Zhang
Pengcheng Zhou
Xiao Zhong
Mingxiang Zou
Yanming Li
Yan Huang
Publication date
01-03-2021
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 1/2021
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-020-00375-6

Other articles of this Issue 1/2021

Infectious Diseases and Therapy 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.